Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07YNM
|
|||
| Former ID |
DNCL003678
|
|||
| Drug Name |
NN8765
|
|||
| Indication | Rheumatoid arthritis [ICD-11: FA20] | Phase 2 | [1] | |
| Company |
Novo Nordisk
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | NKG2-A/B-activating NK receptor (NKG2A) | Target Info | Modulator | [2] |
| KEGG Pathway | Antigen processing and presentation | |||
| Natural killer cell mediated cytotoxicity | ||||
| Graft-versus-host disease | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| WikiPathways | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Innate Pharma. | |||
| REF 2 | Handbook of Therapeutic Antibodies. 2014. 1. Page(1098). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.